Comparative Anti-Reflux Procedures in Neurologically Impaired Children
NCT ID: NCT01307982
Last Updated: 2013-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
3 participants
INTERVENTIONAL
2011-01-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fundoplication
During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
Fundoplication
During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
Gastrojejunal (GJ) feeding tube
Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
Gastrojejunal (GJ) feeding tube
Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fundoplication
During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
Gastrojejunal (GJ) feeding tube
Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient has functional impairment classified by either gross motor functional classification of 3, 4 or 5 OR impaired function in walking, crawling/standing, rolling/sitting, arm use, hand use, ability to hold head up; AND
* patient has a gastrostomy; AND
* patient has intolerance of feedings or other complications attributed to GERD as defined below; AND
* patient has a positive GERD diagnostic evaluation as define below:
* GERD diagnostic evaluation will include the following investigations;
* endoscopy and biopsy for visual assessment and histology of the esophageal mucosa
* pH study and/or multichannel intraluminal impedance (MII) probe to detect and quantify gastroesophageal reflux
* GER demonstrated by:
* Reflux Esophagitis: Endoscopic appearance of mucosal breaks in the distal esophagus with or without pathologist diagnosis based on one or more biopsy histologic features of: inflammatory cellular infiltrate, basal cell hyperplasia, elongation of the vascular papillae AND no infectious microorganisms and \< 15 eosinophils per high power field; OR
* pH OR pH/multichannel intraluminal impedance(MII) probe evidence of pathologic GER:
* pH probe: acid reflux index \> 7 % OR
* pH/MII reflux symptom-associated acid or non-acid volume associated reflux events;
* Upper GI will only be used to determine normal anatomy; AND
* patient has either medically refractory GERD or severe GERD as defined below:
* Medically refractory GERD - GERD that has not responded to 12 weeks of treatment with a proton pump inhibitor (PPI) (and verified gastric pH \> 4) and/or trial of continuous intragastric feedings and has one of the following complications:
* Esophagitis: Endoscopic appearance of mucosal breaks in the distal esophagus with or without pathologist diagnosis based on one or more biopsy histologic features of: inflammatory cellular infiltrate, basal cell hyperplasia, elongation of the vascular papillae
* Failure to thrive: diminishing weight percentile for age or weight for age z-score sustained over 6 months.
* Pneumonia consistent with aspiration,
* Acute life threatening event,
* Severe GERD - at least one severe complication of GERD and patient cannot safely tolerate a trial of medical management due to one of the following life-threatening complications:
* aspiration pneumonia,
* acute life threatening event (ALTE),
* complete loss of airway protection (absent cough/gag) AND,
* Upper GI barium contrast study for anatomy; AND
* Barium pharyngeal swallow study or modified barium swallow study or Flexible Endoscopic Evaluation of Swallowing (FEES) in past year; AND
* the parent or legal guardian speaks English or Spanish (the only two languages in which the instruments are standardized)
Exclusion Criteria
* Upper GI findings show uncorrected distal gastrointestinal obstruction including: gastric outlet obstruction, duodenal obstruction, malrotation; OR
* Upper GI demonstrates structural foregut abnormalities that preclude a fundoplication including: microgastria, short esophagus, high anesthetic risk; OR
* Diagnosis or history of congenital diaphragmatic hernia, esophageal atresia, chronic intestinal pseudoobstruction; OR
* Endoscopy and biopsy demonstrates esophagitis from causes other than GER including: eosinophilic esophagitis, candida esophagitis, viral esophagitis); OR
* Rapidly changing or indeterminate neurological including either a deteriorating neurological condition such as rapid loss of developmental milestones or improving, such as rapid recovery following severe neurological insult; OR
* Patient has unacceptable general anesthetic risk; OR
* A previous Nissen fundoplication; OR
* Feeds delivered by GJ/NJ at the time of enrollment occurring for greater than 3 months.
6 Months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Utah
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Raj Srivastava
Dr. Raj Srivastava, MD, MPH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raj Srivastava, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Utah
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Primary Children's Medical Center
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00043616
Identifier Type: -
Identifier Source: org_study_id